Immunity Immunity
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Male and female Healthy volunteer aged 20-45 years; No significant underlying disease; All patients will be informed both verbally and in writing of the possible risks and adverse events which may occur during the study and must sign the written consent forms to participate in the study.
Exclusion criteria
Exclusion criteria: Abnormal finding after physical examination BMI more than or equal to 25 kg/m2 Clinically significant abnormalities in blood chemistry and hematology: o Hemoglobin < 10 g/dL o White blood cells < 4,000 per cu. mm. o Platelets < 100,000 per cu. mm. o Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase more than 2 times the upper limit of normal o Blood urea nitrogen (BUN) more than 20 mg/dL, creatinine more than 1.5 times the upper limit of normal o Abnormal urine examination o Prothrombin time (PT) more than 13.0 sec, international normalized ratio (INR) more than 5, or partial thromboplastin time (PTT) more than 38.9 sec Unable to participate throughout the study period Have a history of hypersensitivity to garlic or black garlic Smoking Pregnant or lactating;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cytokines Day 0, 1, 28, 56 ELISA,White blood cells Day 0, 1, 28, 56 Flow cytometry | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet aggregation Day 0, 28, 56 Platelet aggregometry,Coagulation Day 0, 28, 56 PT, PTT, INR,Safety Day 0, 14, 28, 56 CBC, BUN, Cr, LFT, U/A,VASP Day 0, 28, 56 VASP phosphorylation assay | — |
Countries
Thailand
Contacts
Department of Pharmacology, Faculty of Medicine, Chiang Mai University